Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge.

Palmer AJ, Si L, Tew M, Hua X, Willis MS, Asseburg C, McEwan P, Leal J, Gray A, Foos V, Lamotte M, Feenstra T, O'Connor PJ, Brandle M, Smolen HJ, Gahn JC, Valentine WJ, Pollock RF, Breeze P, Brennan A, Pollard D, Ye W, Herman WH, Isaman DJ, Kuo S, Laiteerapong N, Tran-Duy A, Clarke PM.

Value Health. 2018 Jun;21(6):724-731. doi: 10.1016/j.jval.2018.02.002. Epub 2018 Apr 9.

2.

Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach.

Pollock RF, Chubb B, Valentine WJ, Heller S.

Diabetes Metab Syndr Obes. 2018 May 16;11:217-226. doi: 10.2147/DMSO.S156739. eCollection 2018.

3.

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK.

Pollock RF, Valentine WJ, Marso SP, Gundgaard J, Hallén N, Hansen LL, Tutkunkardas D, Buse JB; DEVOTE Study Group.

Diabetes Ther. 2018 Jun;9(3):1217-1232. doi: 10.1007/s13300-018-0430-4. Epub 2018 Apr 30.

4.

An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland.

Pollock RF, Meckley LM.

Clinicoecon Outcomes Res. 2018 Apr 10;10:223-229. doi: 10.2147/CEOR.S155641. eCollection 2018.

5.

Correction to: Lane et al., Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.

Lane W, Weatherall J, Gundgaard J, Pollock RF.

J Med Econ. 2018 May;21(5):542. doi: 10.1080/13696998.2018.1452510. Epub 2018 Mar 21. No abstract available.

PMID:
29560778
6.

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.

Wilkinson L, Hunt B, Johansen P, Iyer NN, Dang-Tan T, Pollock RF.

Diabetes Ther. 2018 Jun;9(3):951-961. doi: 10.1007/s13300-018-0402-8. Epub 2018 Mar 19.

7.

Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation.

Valentine WJ, Van Brunt K, Boye KS, Pollock RF.

Appl Health Econ Health Policy. 2018 Jun;16(3):357-366. doi: 10.1007/s40258-018-0379-5.

PMID:
29525908
8.

Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden.

Jendle J, Ericsson Å, Hunt B, Valentine WJ, Pollock RF.

Diabetes Ther. 2018 Feb;9(1):87-99. doi: 10.1007/s13300-017-0344-6. Epub 2017 Dec 4.

9.

Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.

Pollock RF, Muduma G.

Expert Opin Drug Deliv. 2017 Dec;14(12):1439-1446. doi: 10.1080/17425247.2017.1393412. Epub 2017 Oct 24.

PMID:
29032713
10.

Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.

Lane WS, Weatherall J, Gundgaard J, Pollock RF.

J Med Econ. 2018 Feb;21(2):144-151. doi: 10.1080/13696998.2017.1384383. Epub 2017 Oct 12.

PMID:
28945173
11.

A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000.

Pollock RF, Muduma G.

Clinicoecon Outcomes Res. 2017 Aug 10;9:475-483. doi: 10.2147/CEOR.S139525. eCollection 2017.

12.

The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus.

Valentine WJ, Pollock RF, Saunders R, Bae J, Norrbacka K, Boye K.

Value Health. 2017 Jul - Aug;20(7):985-991. doi: 10.1016/j.jval.2016.12.001. Epub 2017 May 4.

13.

Patient safety during procedural sedation using capnography monitoring: a systematic review and meta-analysis.

Saunders R, Struys MMRF, Pollock RF, Mestek M, Lightdale JR.

BMJ Open. 2017 Jun 30;7(6):e013402. doi: 10.1136/bmjopen-2016-013402. Review.

14.

Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant.

Muduma G, Saunders R, Odeyemi I, Pollock RF.

PLoS One. 2016 Nov 3;11(11):e0160421. doi: 10.1371/journal.pone.0160421. eCollection 2016. Review.

16.

A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.

Pollock RF, Tikkanen CK.

J Med Econ. 2017 Mar;20(3):213-220. doi: 10.1080/13696998.2016.1245663. Epub 2016 Oct 24.

PMID:
27705031
17.

A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK.

Muduma G, Odeyemi I, Pollock RF.

J Med Econ. 2016 Oct;19(10):995-1002. doi: 10.1080/13696998.2016.1189921. Epub 2016 Jun 1.

PMID:
27172118
18.

Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients.

Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF.

Adv Ther. 2016 Mar;33(3):345-56. doi: 10.1007/s12325-016-0292-y. Epub 2016 Feb 23. Review.

PMID:
26905265
19.

Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.

Bruhn D, Martin AA, Tavares R, Hunt B, Pollock RF.

J Med Econ. 2016 Jul;19(7):672-83. doi: 10.3111/13696998.2016.1154567. Epub 2016 Mar 2.

PMID:
26882484
20.

Verification and Validation of Health Economic Models for Diabetes.

Boye KS, Lage ME, Lage MJ, Valentine WJ, Pollock RF, Saunders R.

Value Health. 2015 Nov;18(7):A702. doi: 10.1016/j.jval.2015.09.2626. Epub 2015 Oct 20. No abstract available.

Supplemental Content

Loading ...
Support Center